Bruce Cozadd, Jazz Pharmaceuticals CEO
Updated: Jazz to buy Chimerix to get brain tumor drug five months ahead of PDUFA
Jazz Pharmaceuticals will buy North Carolina biotech Chimerix for $935 million in cash, the companies said Wednesday morning.
Through the deal …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
